MoonLake Immunotherapeutics (MLTX) Financials

MoonLake Immunotherapeutics (NASDAQ: MLTX) remains a development-stage biotechnology company with no reported revenue. Total revenue and gross profit were zero in every income statement provided, from 2022 through the second quarter of 2026. As a result, the company’s financial performance continues to depend on research progress, potential commercialization, and its ability to raise capital rather than on operating revenue.

The company’s quarterly net losses have generally expanded as its development programs have advanced. Net loss attributable to common shareholders increased from approximately $9.0 million in Q1 2023 to $55.2 million in Q2 2025, $69.7 million in Q1 2026, and $61.8 million in Q2 2026. The latest loss improved sequentially, but remained above the comparable 2025 quarter’s $56.1 million loss.

Research and development spending is the primary driver of the losses. R&D expense rose from $7.4 million in Q1 2023 to $23.7 million in Q2 2024, $49.8 million in Q2 2025, and $50.2 million in Q2 2026. Selling, general and administrative expense also increased to $11.4 million in Q2 2026 from $6.9 million in Q2 2024. This spending may support clinical and regulatory progress, but it also increases the amount of capital the company must consume before generating revenue.

Operating cash flow has been consistently negative. Quarterly cash used in operating activities increased from $9.0 million in Q1 2023 to $27.9 million in Q2 2024 and $54.5 million in Q2 2025. The burn rate remained elevated at $55.6 million in Q2 2026, although that was an improvement from the $66.3 million used in Q1 2026. Non-cash adjustments and working-capital movements sometimes reduced or increased the gap between net loss and cash burn, but the underlying business has not yet produced operating cash.

Liquidity strengthened significantly during the latest quarter because of external financing. Cash and equivalents increased from $298.5 million at March 31, 2026, to $477.9 million at June 30, 2026. Including short-term investments, readily available liquidity was approximately $537.0 million at quarter-end. At the Q2 operating cash-burn rate, that balance represents roughly two and a half years of funding before considering changes in spending, investment income, milestone payments, or additional financing.

However, much of the Q2 cash increase came from financing rather than operations. MoonLake reported $189.8 million of debt issuance and $44.3 million of common-equity issuance during the quarter. Long-term debt increased to $99.5 million from $73.4 million in Q2 2025, while cash interest paid rose to $2.1 million in Q2 2026 from zero in Q1 2025. The financing provides flexibility, but increases leverage, interest costs, and potential shareholder dilution.

• Liquidity improved: Cash and short-term investments totaled approximately $537.0 million at June 30, 2026, up from about $425.1 million at June 30, 2025.
• Sequential cash burn moderated: Operating cash outflow improved to $55.6 million in Q2 2026 from $66.3 million in Q1 2026.
• Strong short-term balance-sheet position: Q2 current assets of $570.0 million compared with current liabilities of $45.4 million, producing substantial near-term liquidity.
• Net loss improved sequentially: The Q2 2026 net loss of $61.8 million was smaller than the $69.7 million loss reported in Q1 2026.
• Investment activity is largely a cash-management function: Purchases and maturities of investments have caused large quarter-to-quarter swings in investing cash flow, but produced only $322,000 of net investing cash inflow in Q2 2026.
• Other income has helped reduce losses: Investment and other income totaled approximately $2.6 million in Q2 2026, partially offsetting $2.6 million of interest expense, but this is not a substitute for product revenue.
• No revenue has been reported: Revenue and gross profit remained at zero across the supplied periods, leaving MoonLake dependent on future clinical and commercial success.
• Operating losses and R&D spending remain elevated: Q2 2026 operating expenses were $61.7 million, including $50.2 million of R&D spending.
• Financing dependence is increasing: Q2’s $234.6 million of financing cash inflow was more than four times the quarter’s operating cash burn, highlighting the company’s reliance on debt and equity markets.
• Dilution and leverage risks are rising: Q2 2026 weighted-average basic shares outstanding were 147.8 million versus 126.6 million in the restated Q2 2025 figure, while long-term debt has also increased.

Overall, MLTX’s balance sheet currently provides a meaningful financial cushion, and the latest financing substantially extended its ability to fund development. The key risks are that cash consumption remains high, retained earnings have deteriorated to approximately -$594.4 million, and the company has yet to establish a revenue stream. For investors, future clinical milestones and evidence that MoonLake can convert its R&D investment into a commercially viable product are likely to matter more than near-term earnings metrics.